Rosetta Genomics said Brian Markison has been named an observer of the company's board.
Pending shareholder approval, he will also become a director, the firm said.
Markison is currently chairman and CEO of King Pharmaceuticals, which was recently acquired by Pfizer. Previously, he held a variety of roles at Bristol-Myers Squibb, including president of oncology/virology and oncology therapeutics.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
